Lindsey Merry L, Iyer Rugmani Padmanabhan, Zamilpa Rogelio, Yabluchanskiy Andriy, DeLeon-Pennell Kristine Y, Hall Michael E, Kaplan Abdullah, Zouein Fouad A, Bratton Dustin, Flynn Elizabeth R, Cannon Presley L, Tian Yuan, Jin Yu-Fang, Lange Richard A, Tokmina-Roszyk Dorota, Fields Gregg B, de Castro Brás Lisandra E
Mississippi Center for Heart Research, Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi; San Antonio Cardiovascular Proteomics Center, University of Texas Health Science Center, San Antonio, Texas; Research Service, G.V. (Sonny) Montgomery Veterans Affairs Medical Center, Jackson, Mississippi.
Mississippi Center for Heart Research, Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi; San Antonio Cardiovascular Proteomics Center, University of Texas Health Science Center, San Antonio, Texas.
J Am Coll Cardiol. 2015 Sep 22;66(12):1364-74. doi: 10.1016/j.jacc.2015.07.035.
Proteolytically released extracellular matrix (ECM) fragments, matricryptins, are biologically active and play important roles in wound healing. Following myocardial infarction (MI), collagen I, a major component of cardiac ECM, is cleaved by matrix metalloproteinases (MMPs).
This study identified novel collagen-derived matricryptins generated post-MI that mediate remodeling of the left ventricle (LV).
Recombinant collagen Ia1 was used in MMPs cleavage assays, the products were analyzed by mass spectrometry for identification of cleavage sites. C57BL6/J mice were given MI and animals were treated either with vehicle control or p1158/59 matricryptin. Seven days post-MI, LV function and parameters of LV remodeling were measured. Levels of p1158/59 were also measured in plasma of MI patients and healthy controls.
In situ, MMP-2 and -9 generate a collagen Iα1 C-1158/59 fragment, and MMP-9 can further degrade it. The C-1158/59 fragment was identified post-MI, both in human plasma and mouse LV, at levels that inversely correlated to MMP-9 levels. We synthesized a peptide beginning at the cleavage site (p1158/59, amino acids 1159 to 1173) to investigate its biological functions. In vitro, p1158/59 stimulated fibroblast wound healing and robustly promoted angiogenesis. In vivo, early post-MI treatment with p1158/59 reduced LV dilation at day 7 post-MI by preserving LV structure (p < 0.05 vs. control). The p1158/59 stimulated both in vitro and in vivo wound healing by enhancing basement membrane proteins, granulation tissue components, and angiogenic factors.
Collagen Iα1 matricryptin p1158/59 facilitates LV remodeling post-MI by regulating scar formation through targeted ECM generation and stimulation of angiogenesis.
蛋白水解释放的细胞外基质(ECM)片段,即基质隐窝蛋白,具有生物活性,在伤口愈合中起重要作用。心肌梗死(MI)后,心脏ECM的主要成分胶原蛋白I被基质金属蛋白酶(MMPs)切割。
本研究鉴定了MI后产生的新型胶原蛋白衍生基质隐窝蛋白,其介导左心室(LV)重塑。
将重组胶原蛋白Ia1用于MMPs切割试验,通过质谱分析产物以鉴定切割位点。对C57BL6/J小鼠进行MI造模,并将动物分为载体对照组或p1158/59基质隐窝蛋白处理组。MI后7天,测量LV功能和LV重塑参数。还测量了MI患者和健康对照者血浆中p1158/59的水平。
在原位,MMP-2和-9产生胶原蛋白Iα1 C-1158/59片段,MMP-9可进一步降解它。在人血浆和小鼠LV中均在MI后鉴定出C-1158/59片段,其水平与MMP-9水平呈负相关。我们合成了一个从切割位点开始的肽段(p1158/59,氨基酸1159至1173)以研究其生物学功能。在体外,p1158/59刺激成纤维细胞伤口愈合并强烈促进血管生成。在体内,MI后早期用p1158/59治疗可通过保留LV结构在MI后第7天减少LV扩张(与对照组相比,p < 0.05)。p1158/59通过增强基底膜蛋白、肉芽组织成分和血管生成因子在体外和体内刺激伤口愈合。
胶原蛋白Iα1基质隐窝蛋白p1158/59通过靶向ECM生成和刺激血管生成来调节瘢痕形成,从而促进MI后LV重塑。